Guardant Health's (GH) Sell (D-) Rating Reaffirmed at Weiss Ratings

Key Points

• Guardant Health's stock has been reaffirmed with a "sell (D-)" rating by Weiss Ratings, amidst mixed opinions from other analysts, with 23 giving a Buy rating.
• Raymond James raised its price target for Guardant Health from $59.00 to $61.00, while Wells Fargo set a target of $72.00 and labeled the stock as "overweight."
• CEO Helmy Eltoukhy sold 300,000 shares of Guardant Health recently, indicating a 12.38% decrease in his ownership, while insider sales totaled nearly $18 million over the last 90 days.

Guardant Health (NASDAQ:GH - Get Free Report)'s stock had its "sell (d-)" rating reiterated by research analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Other analysts also recently issued reports about the stock. Raymond James Financial upped their price objective on shares of Guardant Health from $59.00 to $61.00 and gave the company an "outperform" rating in a report on Thursday, July 31st. Cowen reaffirmed a "buy" rating on shares of Guardant Health in a report on Thursday, September 25th. Wells Fargo & Company assumed coverage on shares of Guardant Health in a report on Monday, September 22nd. They issued an "overweight" rating and a $72.00 price objective on the stock. William Blair reaffirmed an "outperform" rating on shares of Guardant Health in a report on Thursday, September 25th. Finally, Mizuho upped their price objective on shares of Guardant Health from $65.00 to $70.00 and gave the company an "outperform" rating in a report on Thursday, September 25th. Twenty-three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $65.86.

Guardant Health Trading Up 3.0%

NASDAQ:GH opened at $65.32 on Wednesday. The company's 50 day moving average is $58.48 and its two-hundred day moving average is $49.89. The company has a market cap of $8.15 billion, a PE ratio of -19.50 and a beta of 1.53. Guardant Health has a twelve month low of $20.14 and a twelve month high of $68.00.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.08. The business had revenue of $232.09 million during the quarter, compared to analysts' expectations of $211.19 million. The firm's revenue was up 31.0% on a year-over-year basis. During the same period last year, the company earned ($0.84) earnings per share. Guardant Health has set its FY 2025 guidance at EPS. As a group, analysts expect that Guardant Health will post -2.9 EPS for the current fiscal year.

Insiders Place Their Bets

In other Guardant Health news, CEO Helmy Eltoukhy sold 300,000 shares of the company's stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total transaction of $17,835,000.00. Following the completion of the transaction, the chief executive officer directly owned 2,123,499 shares in the company, valued at approximately $126,242,015.55. This represents a 12.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Medina Manuel Hidalgo sold 2,165 shares of the company's stock in a transaction on Friday, September 12th. The stock was sold at an average price of $54.16, for a total transaction of $117,256.40. Following the transaction, the director owned 851 shares of the company's stock, valued at $46,090.16. This represents a 71.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 302,691 shares of company stock valued at $17,981,965 over the last 90 days. 6.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Guardant Health

Several hedge funds and other institutional investors have recently modified their holdings of GH. Driehaus Capital Management LLC acquired a new position in Guardant Health during the first quarter worth about $82,349,000. ARK Investment Management LLC boosted its position in Guardant Health by 100.4% during the second quarter. ARK Investment Management LLC now owns 2,823,497 shares of the company's stock worth $146,935,000 after acquiring an additional 1,414,381 shares during the last quarter. Invesco Ltd. boosted its position in Guardant Health by 100.9% during the first quarter. Invesco Ltd. now owns 2,794,667 shares of the company's stock worth $119,053,000 after acquiring an additional 1,403,670 shares during the last quarter. Norges Bank acquired a new position in Guardant Health during the second quarter worth about $64,136,000. Finally, Franklin Resources Inc. boosted its position in Guardant Health by 78.2% during the second quarter. Franklin Resources Inc. now owns 2,319,947 shares of the company's stock worth $120,730,000 after acquiring an additional 1,018,144 shares during the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.